A diagram of four deadly pancreatic cancer chemotherapy drugs has almost doubled compared to standard chemotherapy of the duration of survival of patients, a new study suggests.
In the late trials, French researchers divided a group of 342 patients with advanced PANCREATIC ADENOCARCINOMA, the most common disease, in two groups form. Gemcitabine half received the standard treatment, while the rest received FOLFIRINOX, a combination of four drugs of Oxaliplatin, irinotecan, leucovorin and fluorouracil.
Time of median survival improved 6.8 months for group gemcitabine 11.1 months in the FOLFIRINOX group, according to the study, which is published in the May 12 of the New England Journal of Medicine. The Group of the combination made suffer more side effects of treatment, however.
"Explain us to patients the benefits and the toxicity of these two patterns,", said Dr. Thierry Conroy, Professor of the University of Nancy-medical oncology and Center Alexis Vautrin in Nancy (France), author of the study. "The FOLFIRINOX schema has managed to stabilize patients longer with the best quality of life and delay of degradation of the quality of life." Unfortunately, it is still a treatment palliative but capable of recording months and sometimes years of life. ?
PANCREATIC ADENOCARCINOMA was the fourth leading cause of death from cancer of the United States in 2010, the study said, and the 5-year survival rate is only 6 per cent in the United States and in Europe.
Participants in the study, whose average age was 61, were still fully active and able to carry out daily activities, and more ill patients were not eligible. The trial was conducted in 15 centers in France the second phase of the trial and extended to 48 centres during the third phase of the trial.
Patients stop study at their request, or if they have experienced unacceptable toxic effects - which included diarrhea, blood cell counts and neuropathy - or evidence of the progression of the disease. A patient in each group died of causes related to the treatment, and 273 of 342 patients had died at the end of the median follow-up period of 26 months.
Dr. Alberto Montero, Professor Assistant of medicine at Sylvester Comprehensive Care Center at the University of Miami Miller School of Medicine, said that the results were "notable" because the FOLFIRINOX group has experienced an improvement in survival rate.
Montero warned, however, that a small minority of patients with PANCREATIC ADENOCARCINOMA corresponds to the State of the patients in the study even conducting normal daily activities. Even newly diagnosed patients are often very sick, he said and would not be able to tolerate the toxic effects of drugs in the combination.
"To see a doubling of survival is impressive," said Montero, also a medical oncologist. "" "". For many reasons, this cancer is highly resistant to chemotherapy. I think that this trial is a first step. ?
No comments:
Post a Comment